• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program

    12/5/23 10:52:59 PM ET
    $ARVN
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARVN alert in real time by email

    NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc. (NYSE:PFE) to discuss vepdegestrant (ARV-471) data presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) as well as plans to expand the vepdegestrant development program.

    Investor Call & Webcast Details

    Arvinas will host a conference call and webcast on Wednesday, December 6 at 7:30 a.m. ET to discuss these updates. Participants are invited to listen by going to the Events and Presentation section under the Investors page on the Arvinas website at www.arvinas.com. A replay of the webcast will be archived on the Arvinas website following the presentation.

    About vepdegestrant (ARV-471)

    Vepdegestrant is an investigational, orally bioavailable PROTAC protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER positive (ER+)/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.

    In preclinical studies, vepdegestrant demonstrated up to 97% ER degradation in tumor cells, induced robust tumor shrinkage when dosed as a single agent in multiple ER-driven xenograft models, and showed increased anti-tumor activity when compared to a standard of care agent, fulvestrant, both as a single agent and in combination with a CDK4/6 inhibitor. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will equally share worldwide development costs, commercialization expenses, and profits. Ongoing and planned clinical trials will continue to monitor and evaluate the safety and anti-tumor activity of vepdegestrant.

    About Arvinas

    Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and "undruggable" targets, the company has three investigational clinical-stage programs: ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer; and vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas, as part of its overall business strategy, selectively assesses opportunities for potential collaboration, license, marketing and royalty arrangements, and similar transactions, to advance and accelerate the development and enhance the commercial potential of its product candidates. For more information, visit www.arvinas.com.

    Arvinas Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the potential advantages and therapeutic benefits of vepdegestrant (ARV-471). All statements, other than statements of historical facts, contained in this press release are forward-looking statements. The words "believe," "expect," "may," "plan," "potential," "will," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

    We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to: our and Pfizer Inc.'s ("Pfizer") performance of our respective obligations with respect to our collaboration with Pfizer; whether we and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant and obtain marketing approval for and commercialize vepdegestrant on our current timelines or at all; whether our cash and cash equivalent resources will be sufficient to fund our foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent other reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this release.

    Investor Contact:

    Jeff Boyle, Arvinas Investor Relations

    347-247-5089

    [email protected]

    Media Contact:

    Kirsten Owens, Arvinas Communications

    203-584-0307

    [email protected]



    Primary Logo

    Get the next $ARVN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARVN
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Arvinas Inc.
    $ARVN
    9/24/2025$10.00Buy → Neutral
    BofA Securities
    Arvinas Inc.
    $ARVN
    9/17/2025$16.00Overweight
    Barclays
    Arvinas Inc.
    $ARVN
    6/2/2025$9.00Outperform → Market Perform
    Leerink Partners
    Arvinas Inc.
    $ARVN
    5/5/2025$11.00Buy → Hold
    Truist
    Arvinas Inc.
    $ARVN
    5/2/2025$10.00Buy → Hold
    Jefferies
    Arvinas Inc.
    $ARVN
    5/2/2025Buy → Hold
    TD Cowen
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Arvinas Inc.
    $ARVN
    3/13/2025$70.00 → $15.00Buy → Neutral
    Goldman
    More analyst ratings

    $ARVN
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hearing Against Pfizer Set For 29 September In Contraceptive 'Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio

    The number of lawsuits filed has tripled to over 1300 since May New US peer-reviewed study adds to body of research confirming link between use of Depo-Provera and increased risk of brain tumours Global pharmaceutical company Pfizer Inc. (NYSE: PFE), manufacturer of contraceptive injection Depo-Provera (DMPA), is facing a multidistrict litigation (MDL No. 3140) in the USA being brought on behalf of women who developed an intracranial meningioma, a type of brain tumour after using Pfizer's Depo-Provera. This litigation followed a study by EPI-PHARE (Roland et al.) published in March 2024 in the British Medical Journal, which found that women who had used the Pfizer contraceptive inje

    9/25/25 3:37:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025

    More than 45 abstracts, including five late-breaking presentations and recognition in Presidential Symposium, showcase impact of approved medicines and potential of next-generation pipeline Pfizer Inc. (NYSE: PFE) will highlight data across its extensive Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany. Data from more than 45 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 11 oral/mini oral presentations and five late-breaking sessions, will be presented across Pfizer's core scientific modalities and key tumor areas. "At ESMO, Pfizer is demonstrating how earlier in

    9/25/25 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 4, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the confer

    9/23/25 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $PFE
    SEC Filings

    View All

    Arvinas Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ARVINAS, INC. (0001655759) (Filer)

    9/17/25 4:32:51 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arvinas Inc.

    SCHEDULE 13G/A - ARVINAS, INC. (0001655759) (Subject)

    8/14/25 1:07:20 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 13F-HR filed by Pfizer Inc.

    13F-HR - PFIZER INC (0000078003) (Filer)

    8/11/25 5:08:12 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Arvinas downgraded by BofA Securities with a new price target

    BofA Securities downgraded Arvinas from Buy to Neutral and set a new price target of $10.00

    9/24/25 7:54:47 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Arvinas with a new price target

    Barclays resumed coverage of Arvinas with a rating of Overweight and set a new price target of $16.00

    9/17/25 7:57:56 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arvinas downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Arvinas from Outperform to Market Perform and set a new price target of $9.00

    6/2/25 8:41:53 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Morrison Briggs bought $227,010 worth of shares (30,000 units at $7.57), increasing direct ownership by 65% to 76,021 units (SEC Form 4)

    4 - ARVINAS, INC. (0001655759) (Issuer)

    9/24/25 9:16:17 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    9/17/25 6:09:28 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    9/3/25 11:31:49 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Morrison Briggs bought $227,010 worth of shares (30,000 units at $7.57), increasing direct ownership by 65% to 76,021 units (SEC Form 4)

    4 - ARVINAS, INC. (0001655759) (Issuer)

    9/24/25 9:16:17 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    10/31/24 4:06:54 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $PFE
    Financials

    Live finance-specific insights

    View All

    Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 4, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the confer

    9/23/25 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

    Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an initial enterprise value of $4.9 billion with a CVR of up to $22.50 per share in additional payments Pfizer to host a public webcast at 8 am EDT today Pfizer Inc. (NYSE:PFE) and Metsera, Inc. (NASDAQ:MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a

    9/22/25 6:45:00 AM ET
    $MTSR
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    – Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in healthy volunteers; initiated dosing in patients with Parkinson's disease – – Presented preclinical data from ARV-393 program demonstrating single-agent activity and favorable combinability profile – – Initiated Phase 1 clinical trial evaluating ARV-806 in patients with solid tumors harboring KRAS G12D mutations – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology compan

    8/6/25 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

    – John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., Chairperson, Chief Executive Officer (CEO) and President at Arvinas, has informed the Board of Directors of his plans to retire from his role as President and CEO following a search for, an

    7/9/25 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dexcom Appoints Jon Coleman as Chief Commercial Officer

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

    3/25/25 4:05:00 PM ET
    $DXCM
    $MASI
    $PFE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations

    FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate

    Industry veteran in clinical development of oncology therapeutics, Dr. Jens Wurthner, PhD, joins as Chief Medical Officer Lead development candidate, FORX-428, a PARG inhibitor for solid tumors, maintains progress toward IND submission by mid-2025 FoRx Therapeutics AG, a Swiss-based company committed to discovering and developing innovative drugs targeting cancer-relevant DDR (DNA Damage Response) pathways, today announced that it has appointed Jens Würthner, MD PhD, as Chief Medical Officer. He is further strengthening FoRx Therapeutics' existing management team with CEO Tarig Bashir, CSO Frank Zenke, and Head of Chemistry Ulrich Lücking. Jens Würthner has 20+ years of clinical devel

    2/26/25 9:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

    SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

    11/14/24 1:22:38 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

    SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

    11/14/24 7:00:23 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

    SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

    9/10/24 10:30:07 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care